Publications 2000
Original Papers
- Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol. 2000; 79(3):110-3.
- Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol. 2000; 11(9):1105-14.
- Franklin J, Paulus U, Lieberz D, Breuer K, Tesch H, Diehl V. Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group. Ann Oncol. 2000; 11(5):617-23.
- Lieberz D, Sextro M, Paulus U, Franklin J, Tesch H, Diehl V. How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group.Ann Hematol. 2000; 79(2):73-8.
- Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 2000; 96(4):1280-6.
- Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol. 2000; 18(2):332-9.
- Schnell R, Vitetta E, Schindler J, Borchmann P, Barth S, Ghetie V, Hell K, Drillich S, Diehl V, Engert A. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia. 2000; 14(1):129-35.
- von Wasielewski R, Seth S, Franklin J, Fischer R, Hübner K, Hansmann ML, Diehl V, Georgii A. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood. 2000; 95(4):1207-13
Reviews
- Breuer K, Diehl V, Rüffer U. [Long-term toxic sequelae of the treatment of Hodgkin's disease]. Med Klin (Munich). 2000; 95(7):378-84.
- Carde P, Cavalli F, Diehl V, Franklin J. Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease? Hematol J. 2000; 1(4):282-90.
- Diehl V, Josting A. Hodgkin's disease. Cancer J. 2000; 6 Suppl 2:S150-8.
- Josting A, Wolf J, Diehl V. Hodgkin disease: prognostic factors and treatment strategies. Curr Opin Oncol. 2000; 12(5):403-11.
- Matthey B, Engert A, Barth S. Recombinant immunotoxins for the treatment of Hodgkin's disease. Int J Mol Med. 2000; 6(5):509-14.
- Sieber M, Engert A, Diehl V. Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group. Ann Oncol. 2000; 11 Suppl 1:81-5.